Access the recording of a webinar workshop focused on Addiction Pharmacology, Psychedelics, and Therapeutic Use To Support Recovery.

Workshop Logistics

• Access to a webpage with a copy of the recording and PDF slides for download are included in registration
• Members of the Resource and Support Program can attend via the Member Portal and do not need to register to attend

Workshop Overview:

Many substances with psychedelic effects are currently regulated as having a high abuse potential and no medical value. However substantial anecdotal, observational, and clinical data suggests that when used within a therapeutic paradigm, many have potential to treat mental health conditions including substance use disorders (SUDs). 

The use of the term psychedelic can encompass several substance classes including tryptamines (e.g. psilocybin), phenethylamines (e.g. MDMA), arylcyclohexlyamines (e.g. ketamine), and cannabinoids (e.g. THC). Each of these classes and the unique aspects of each drug within the class have variable pharmacology that may give rise to addictive properties. Conversely, unique properties relating to different psychedelics could also enhance potential for treatment of SUDs.

Models of chemical addiction link substances with diverse mechanisms to their ability to cause pleasurable and reinforcing effects via increased dopamine neurotransmission in key brain regions. Other aspects of drug use such as route of administration and environmental factors could also influence patterns of dopamine release or drug effects that reinforce behavior and increase risks of addiction. 

While it’s apparent that many psychedelics do not have ‘high abuse potential’ and some have considerable therapeutic potential in treating SUDs, it’s also prudent to consider that some psychedelics could be habit forming, reinforcing, and addictive. In this webinar workshop we will aim to strike a balanced and data-driven perspective to addiction pharmacology as it relates to psychedelics. 

By examining each class of psychedelic and reviewing their pro- and anti-addictive properties and mechanisms we can sensibly stratify them into low, moderate, and high risks for addiction. We can then generate logical plans that maximize safety and chances of benefit in persons approaching psychedelics for help with SUDs or as part of their recovery path.

Webinar Objectives

• Describe the chemical theory of addiction and compare the pharmacologic profiles and addiction risks of various psychedelics
• Outline mechanisms of psychedelics that could contribute to therapeutic benefits in persons with SUDs
• Summarize clinical research involving psychedelic and substance use disorders
• Discuss contraindications and other clinical considerations of using psychedelics safely in the context of substance use disorders

Registration is 20$ and includes the webinar workshop recording page as well as downloadable PDF slides.
 

Webinar Disclaimer

This webinar is for information and educational purposes only. It is not meant to condone or encourage the use of illicit substances. The information presented is not medical advice and should not be taken as such. It is recommended you follow laws applicable to your jurisdiction.